The content on this site is intended for healthcare professionals only
Dr Fedor Moiseenko speaks to ecancer about an extended 36 months follow-up of the phase III trial DOMAJOR.
The results showed that prolgolimab plus pemetrexed and platinum-based chemotherapy provides sustained survival benefits over chemotherapy alone in patients with advanced nonsquamous NSCLC, with efficacy maintained across PD-L1 subgroups.
After a median follow-up of 35.9 months, median overall survival was 28.1 months with prolgolimab versus 14.9 months with chemotherapy alone, while progression-free survival and objective response rates were also improved.
Dr Moiseenko also covers the long-term safety profile, including treatment-related adverse events and treatment discontinuations.
JS207 plus chemotherapy enables surgery and deep pathological responses in unresectable NSCLC
Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC
Is radiotherapy a back up plan after neoadjuvant chemo-immunotherapy in perioperative lung cancer management?
Setidegrasib shows promising activity in KRAS G12D-mutated advanced NSCLC
MK-1084 plus pembrolizumab achieves high response rates in KRAS G12C mutated non-small cell lung cancer
Durvalumab improves survival and delays progression in limited-stage small cell lung cancer
Osimertinib plus local therapy improves outcomes in EGFR-mutant metastatic lung cancer
Pembrolizumab plus chemotherapy delivers lasting benefit in early-stage NSCLC
Lurbinectedin plus atezolizumab improves PFS and OS in ES-SCLC first-line maintenance
